Clinical Trial Update: An Efficacy and Safety Study of Hydromorphone Hydrochloride (HCl) Oral Osmotic System (OROS) in the Reduction of Breakthrough Pain Medication Frequency in Participants With Cancer [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating Hydromorphone hydrochloride OROS for reducing breakthrough pain medication use in cancer patients, with efficacy and safety results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Hydromorphone HCl OROS (hydromorphone hydrochloride)

Snippet

Sponsor: Janssen Korea, Ltd., Korea | Conditions: Cancer, Pain | Phase 4 | Status: COMPLETED | Results posted: 2013-08-08